Noctrix Health just turned late-night pacing into a venture capital headline. The Pleasanton-based medtech company secured up to $33.5 million in new financing, a mix of equity and debt, to accelerate U.S. commercialization of its Nidra Therapy for Restless Legs Syndrome. Millions of people wrestle with RLS every night, and Noctrix Health is tackling it with a wearable neuromodulation device that doesn’t sedate the brain but wires relief directly into the muscles. That’s not just incremental, it’s a rethink of how chronic conditions should be treated.
The investor lineup shows this is bigger than a moonshot. Blue Venture Fund, aligned with the vast Blue Cross Blue Shield network, stepped in with Sandbox Clinical Ventures, both represented by Dr. Emir Sandhu. Their presence is about more than money, it’s access to one in three Americans. Bridge Bank, led by Bill Wickline and its Life Sciences team, provided the debt facility, adding financial leverage to the push. This is a group betting on adoption at scale, not boutique science projects.
This round stacks on top of serious capital already raised. A $40 million Series C in 2024 led by Sectoral Asset Management drew in Angelini Ventures, ResMed, and Asahi Kasei, with OrbiMed and Treo Ventures backing again. Before that, a $17 million Series B in 2021 gave Noctrix Health its first big growth push. Total funding now clears the $90 million mark, and every dollar has been paired with clinical milestones and FDA approvals.
The science is as strong as the syndicate. The Nidra TOMAC System isn’t promising, it’s proven. Ninety-one percent of users experienced symptom relief. Patients went from nearly six nights of misery per week to three. The RESTFUL trial hit statistical significance on all seven efficacy outcomes, and the THRIVE study is showing patients not only improve scores but reduce medication doses by an average of 62 percent. That’s not marketing spin, it’s clinical behavior change playing out in the real world.
Behind the therapy is a leadership crew built to scale. Founder and CEO Shriram Raghunathan, trained at Purdue and Stanford, turned neuromodulation expertise into company-building grit. Co-founder and Chief Scientific Officer Jonathan Charlesworth brings Princeton and UCSF neuroscience rigor. The commercial side is in the hands of Ivan Lubogo, whose time at Inspire Medical Systems proved he knows how to make sleep therapies mainstream. On the board, Mark Verratti of Myriad Genetics adds global operating firepower, with decades of experience scaling devices at Cyberonics and LivaNova.
This $33.5 million infusion isn’t just a round, it’s an accelerant. With CMS reimbursement codes already live and the American Academy of Sleep Medicine recognizing the science, Noctrix Health is positioned to turn restless nights into a billion-dollar market opportunity. For the estimated three million Americans who can’t find relief in current drugs, the shift from pills to pulses is about to get very real.
